A dose-ranging study of the effects of mequitazine on actual driving, memory and psychomotor performance as compared to dexchlorpheniramine, cetirizine and placebo - PubMed (original) (raw)
Clinical Trial
A dose-ranging study of the effects of mequitazine on actual driving, memory and psychomotor performance as compared to dexchlorpheniramine, cetirizine and placebo
E L Theunissen et al. Clin Exp Allergy. 2004 Feb.
Abstract
Background: Mequitazine is a so-called 'non-sedative' second-generation antihistamine even though it has never been firmly established that this drug's sedative potential actually differs from that of the 'sedative' first-generation antihistamines.
Objective: The present study compares the sedative effects of three doses of mequitazine on actual driving, psychomotor performance and memory with those of a first- and a second-generation antihistamine.
Methods: Eighteen healthy volunteers received on separate days a single dose of 5, 10 and 15 mg mequitazine, 10 mg cetirizine, 6 mg dexchlorpheniramine and placebo. Drug effects were assessed using two actual driving tests (highway-driving test and car-following test), cognitive and psychometric tests (tracking, divided attention, memory, reasoning and critical flicker fusion), pupil size and questionnaires.
Results: Highway-driving data revealed an overall effect of Treatment on the standard deviation of lateral position (SDLP). Dexchlorpheniramine impaired driving performance as indicated by a significant rise in SDLP. Mequitazine significantly increased SDLP in a dose-related manner, but the separate dose effects failed to reach statistical significance. Divided attention performance was also affected by Treatment. Reaction time (RT) during mequitazine treatments increased in a dose-related manner and significantly differed from placebo at the highest dose. Subjects reported to be less alert after treatment with dexchlorpheniramine. Cetirizine did not affect performance in any of the tasks.
Conclusion: It was concluded that mequitazine is mildly sedating. The effects of mequitazine are comparable to those of other second-generation antihistamines, in that it causes mild driving impairment, particularly at higher doses.
Similar articles
- On-the-road driving performance after use of the antihistamines mequitazine and l-mequitazine, alone and with alcohol.
van der Sluiszen NN, Vermeeren A, Jongen S, Theunissen EL, van Oers AC, Van Leeuwen CJ, Maret A, Desforges C, Delarue A, Ramaekers JG. van der Sluiszen NN, et al. Psychopharmacology (Berl). 2016 Sep;233(18):3461-9. doi: 10.1007/s00213-016-4386-7. Epub 2016 Aug 4. Psychopharmacology (Berl). 2016. PMID: 27488192 Free PMC article. Clinical Trial. - Repeated-dose effects of mequitazine, cetirizine and dexchlorpheniramine on driving and psychomotor performance.
Theunissen EL, Vermeeren A, Ramaekers JG. Theunissen EL, et al. Br J Clin Pharmacol. 2006 Jan;61(1):79-86. doi: 10.1111/j.1365-2125.2005.02524.x. Br J Clin Pharmacol. 2006. PMID: 16390354 Free PMC article. Clinical Trial. - Lack of interaction between two antihistamines, mizolastine and cetirizine, and ethanol in psychomotor and driving performance in healthy subjects.
Patat A, Stubbs D, Dunmore C, Ulliac N, Sexton B, Zieleniuk I, Irving A, Jones W. Patat A, et al. Eur J Clin Pharmacol. 1995;48(2):143-50. doi: 10.1007/BF00192740. Eur J Clin Pharmacol. 1995. PMID: 7589029 Clinical Trial. - Antihistamines and driving ability: evidence from on-the-road driving studies during normal traffic.
Verster JC, Volkerts ER. Verster JC, et al. Ann Allergy Asthma Immunol. 2004 Mar;92(3):294-303; quiz 303-5, 355. doi: 10.1016/S1081-1206(10)61566-9. Ann Allergy Asthma Immunol. 2004. PMID: 15049392 Review. - Antidepressants and driver impairment: empirical evidence from a standard on-the-road test.
Ramaekers JG. Ramaekers JG. J Clin Psychiatry. 2003 Jan;64(1):20-9. J Clin Psychiatry. 2003. PMID: 12590619 Review.
Cited by
- Usefulness of driver's eye movement measurement to detect potential risks under combined conditions of taking second-generation antihistamines and calling tasks.
Sagara A, Nagahama A, Aki H, Yoshimura H, Hiraide M, Shimizu T, Sano M, Yumoto T, Hosoe T, Tanaka K. Sagara A, et al. J Pharm Health Care Sci. 2024 Oct 2;10(1):62. doi: 10.1186/s40780-024-00383-5. J Pharm Health Care Sci. 2024. PMID: 39354647 Free PMC article. - Effects of sedative and non-sedative H1 antagonists on cognitive tasks: behavioral and near-infrared spectroscopy (NIRS) examinations.
Tsujii T, Yamamoto E, Ohira T, Saito N, Watanabe S. Tsujii T, et al. Psychopharmacology (Berl). 2007 Sep;194(1):83-91. doi: 10.1007/s00213-007-0814-z. Epub 2007 May 30. Psychopharmacology (Berl). 2007. PMID: 17534605 Clinical Trial. - The Usage of Histamine Type 1 Receptor Antagonist and Risk of Dementia in the Elderly: A Nationwide Cohort Study.
Yang CC, Chien WC, Chung CH, Lai CY, Tzeng NS. Yang CC, et al. Front Aging Neurosci. 2022 Mar 18;14:811494. doi: 10.3389/fnagi.2022.811494. eCollection 2022. Front Aging Neurosci. 2022. PMID: 35370616 Free PMC article. - On-the-road driving performance after use of the antihistamines mequitazine and l-mequitazine, alone and with alcohol.
van der Sluiszen NN, Vermeeren A, Jongen S, Theunissen EL, van Oers AC, Van Leeuwen CJ, Maret A, Desforges C, Delarue A, Ramaekers JG. van der Sluiszen NN, et al. Psychopharmacology (Berl). 2016 Sep;233(18):3461-9. doi: 10.1007/s00213-016-4386-7. Epub 2016 Aug 4. Psychopharmacology (Berl). 2016. PMID: 27488192 Free PMC article. Clinical Trial. - The role of P-glycoprotein in CNS antihistamine effects.
Conen S, Theunissen EL, Vermeeren A, van Ruitenbeek P, Stiers P, Mehta MA, Toennes SW, Ramaekers JG. Conen S, et al. Psychopharmacology (Berl). 2013 Sep;229(1):9-19. doi: 10.1007/s00213-013-3075-z. Epub 2013 Apr 7. Psychopharmacology (Berl). 2013. PMID: 23564211 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources